187 related articles for article (PubMed ID: 30559935)
1. Limitations of current
Rogers HA; Chapman R; Kings H; Allard J; Barron-Hastings J; Pajtler KW; Sill M; Pfister S; Grundy RG
Oncotarget; 2018 Nov; 9(92):36530-36541. PubMed ID: 30559935
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of histopathological ependymoma variants.
Neumann JE; Spohn M; Obrecht D; Mynarek M; Thomas C; Hasselblatt M; Dorostkar MM; Wefers AK; Frank S; Monoranu CM; Koch A; Witt H; Kool M; Pajtler KW; Rutkowski S; Glatzel M; Schüller U
Acta Neuropathol; 2020 Feb; 139(2):305-318. PubMed ID: 31679042
[TBL] [Abstract][Full Text] [Related]
3. Supratentorial and spinal pediatric ependymomas display a hypermethylated phenotype which includes the loss of tumor suppressor genes involved in the control of cell growth and death.
Rogers HA; Kilday JP; Mayne C; Ward J; Adamowicz-Brice M; Schwalbe EC; Clifford SC; Coyle B; Grundy RG
Acta Neuropathol; 2012 May; 123(5):711-25. PubMed ID: 22109108
[TBL] [Abstract][Full Text] [Related]
4. The BET Inhibitor OTX015 Exhibits In Vitro and In Vivo Antitumor Activity in Pediatric Ependymoma Stem Cell Models.
Servidei T; Meco D; Martini M; Battaglia A; Granitto A; Buzzonetti A; Babini G; Massimi L; Tamburrini G; Scambia G; Ruggiero A; Riccardi R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668642
[TBL] [Abstract][Full Text] [Related]
5. Weighing ependymoma as an epigenetic disease.
Stuckert A; Bertrand KC; Wang P; Smith A; Mack SC
J Neurooncol; 2020 Oct; 150(1):57-61. PubMed ID: 32964355
[TBL] [Abstract][Full Text] [Related]
6. Supratentorial ependymoma in childhood: more than just RELA or YAP.
Zschernack V; Jünger ST; Mynarek M; Rutkowski S; Garre ML; Ebinger M; Neu M; Faber J; Erdlenbruch B; Claviez A; Bielack S; Brozou T; Frühwald MC; Dörner E; Dreschmann V; Stock A; Solymosi L; Hench J; Frank S; Vokuhl C; Waha A; Andreiuolo F; Pietsch T
Acta Neuropathol; 2021 Mar; 141(3):455-466. PubMed ID: 33481105
[TBL] [Abstract][Full Text] [Related]
7. Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells.
Barszczyk M; Buczkowicz P; Castelo-Branco P; Mack SC; Ramaswamy V; Mangerel J; Agnihotri S; Remke M; Golbourn B; Pajovic S; Elizabeth C; Yu M; Luu B; Morrison A; Adamski J; Nethery-Brokx K; Li XN; Van Meter T; Dirks PB; Rutka JT; Taylor MD; Tabori U; Hawkins C
Acta Neuropathol; 2014 Dec; 128(6):863-77. PubMed ID: 25120190
[TBL] [Abstract][Full Text] [Related]
8. Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain.
Gojo J; Lötsch D; Spiegl-Kreinecker S; Pajtler KW; Neumayer K; Korbel P; Araki A; Brandstetter A; Mohr T; Hovestadt V; Chavez L; Kirchhofer D; Ricken G; Stefanits H; Korshunov A; Pfister SM; Dieckmann K; Azizi AA; Czech T; Filipits M; Kool M; Peyrl A; Slavc I; Berger W; Haberler C
Neuro Oncol; 2017 Sep; 19(9):1183-1194. PubMed ID: 28371821
[TBL] [Abstract][Full Text] [Related]
9. Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging.
Pagès M; Pajtler KW; Puget S; Castel D; Boddaert N; Tauziède-Espariat A; Picot S; Debily MA; Kool M; Capper D; Sainte-Rose C; Chrétien F; Pfister SM; Pietsch T; Grill J; Varlet P; Andreiuolo F
Brain Pathol; 2019 May; 29(3):325-335. PubMed ID: 30325077
[TBL] [Abstract][Full Text] [Related]
10. DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment.
Witt H; Gramatzki D; Hentschel B; Pajtler KW; Felsberg J; Schackert G; Löffler M; Capper D; Sahm F; Sill M; von Deimling A; Kool M; Herrlinger U; Westphal M; Pietsch T; Reifenberger G; Pfister SM; Tonn JC; Weller M;
Neuro Oncol; 2018 Nov; 20(12):1616-1624. PubMed ID: 30053291
[TBL] [Abstract][Full Text] [Related]
11. Medulloblastoma and ependymoma cells display increased levels of 5-carboxylcytosine and elevated
Ramsawhook A; Lewis L; Coyle B; Ruzov A
Clin Epigenetics; 2017; 9():18. PubMed ID: 28228863
[TBL] [Abstract][Full Text] [Related]
12. TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma.
Thomas C; Thierfelder F; Träger M; Soschinski P; Müther M; Edelmann D; Förster A; Geiler C; Kim HY; Filipski K; Harter PN; Schittenhelm J; Eckert F; Ntoulias G; May SA; Stummer W; Onken J; Vajkoczy P; Schüller U; Heppner FL; Capper D; Koch A; Kaul D; Paulus W; Hasselblatt M; Schweizer L
Acta Neuropathol; 2021 Jun; 141(6):959-970. PubMed ID: 33755803
[TBL] [Abstract][Full Text] [Related]
13. Clinically aggressive pediatric spinal ependymoma with novel MYC amplification demonstrates molecular and histopathologic similarity to newly described MYCN-amplified spinal ependymomas.
Shatara M; Schieffer KM; Klawinski D; Thomas DL; Pierson CR; Sribnick EA; Jones J; Rodriguez DP; Deeg C; Hamelberg E; LaHaye S; Miller KE; Fitch J; Kelly B; Leraas K; Pfau R; White P; Magrini V; Wilson RK; Mardis ER; Abdelbaki MS; Finlay JL; Boué DR; Cottrell CE; Ghasemi DR; Pajtler KW; Osorio DS
Acta Neuropathol Commun; 2021 Dec; 9(1):192. PubMed ID: 34895332
[TBL] [Abstract][Full Text] [Related]
14. Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas.
Pajtler KW; Wen J; Sill M; Lin T; Orisme W; Tang B; Hübner JM; Ramaswamy V; Jia S; Dalton JD; Haupfear K; Rogers HA; Punchihewa C; Lee R; Easton J; Wu G; Ritzmann TA; Chapman R; Chavez L; Boop FA; Klimo P; Sabin ND; Ogg R; Mack SC; Freibaum BD; Kim HJ; Witt H; Jones DTW; Vo B; Gajjar A; Pounds S; Onar-Thomas A; Roussel MF; Zhang J; Taylor JP; Merchant TE; Grundy R; Tatevossian RG; Taylor MD; Pfister SM; Korshunov A; Kool M; Ellison DW
Acta Neuropathol; 2018 Aug; 136(2):211-226. PubMed ID: 29909548
[TBL] [Abstract][Full Text] [Related]
15. Characterization of global 5-hydroxymethylcytosine in pediatric posterior fossa ependymoma.
Wu T; Zhang ZW; Li S; Wang B; Yang Z; Li P; Zhang J; Tong WM; Li C; Zhao F; Niu Y; Liu P
Clin Epigenetics; 2020 Jan; 12(1):19. PubMed ID: 31992357
[TBL] [Abstract][Full Text] [Related]
16. A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat.
Milde T; Kleber S; Korshunov A; Witt H; Hielscher T; Koch P; Kopp HG; Jugold M; Deubzer HE; Oehme I; Lodrini M; Gröne HJ; Benner A; Brüstle O; Gilbertson RJ; von Deimling A; Kulozik AE; Pfister SM; Martin-Villalba A; Witt O
Acta Neuropathol; 2011 Nov; 122(5):637-50. PubMed ID: 21863243
[TBL] [Abstract][Full Text] [Related]
17. Ependymoma Pediatric Brain Tumor Protein Fingerprinting by Integrated Mass Spectrometry Platforms: A Pilot Investigation.
Rossetti DV; Massimi L; Martelli C; Vincenzoni F; Di Silvestre S; Scorpio G; Tamburrini G; Caldarelli M; Urbani A; Desiderio C
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32183175
[TBL] [Abstract][Full Text] [Related]
18. Ependymoma relapse goes along with a relatively stable epigenome, but a severely altered tumor morphology.
Yang D; Holsten T; Börnigen D; Frank S; Mawrin C; Glatzel M; Schüller U
Brain Pathol; 2021 Jan; 31(1):33-44. PubMed ID: 32633004
[TBL] [Abstract][Full Text] [Related]
19. The genetic and epigenetic basis of ependymoma.
Mack SC; Taylor MD
Childs Nerv Syst; 2009 Oct; 25(10):1195-201. PubMed ID: 19536551
[TBL] [Abstract][Full Text] [Related]
20. Supratentorial non-RELA, ZFTA-fused ependymomas: a comprehensive phenotype genotype correlation highlighting the number of zinc fingers in ZFTA-NCOA1/2 fusions.
Tauziède-Espariat A; Siegfried A; Nicaise Y; Kergrohen T; Sievers P; Vasiljevic A; Roux A; Dezamis E; Benevello C; Machet MC; Michalak S; Puiseux C; Llamas-Gutierrez F; Leblond P; Bourdeaut F; Grill J; Dufour C; Guerrini-Rousseau L; Abbou S; Dangouloff-Ros V; Boddaert N; Saffroy R; Hasty L; Wahler E; Pagès M; Andreiuolo F; Lechapt E; Chrétien F; Blauwblomme T; Beccaria K; Pallud J; Puget S; Uro-Coste E; Varlet P;
Acta Neuropathol Commun; 2021 Aug; 9(1):135. PubMed ID: 34389065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
